Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie has acquired Aliada Therapeutics for $1.4 billion, gaining access to a phase I anti-amyloid antibody and a novel platform for efficient blood-brain barrier transport. Meanwhile, the FDA's accelerated approval program is facing setbacks as therapies for rare and neurological diseases earn accelerated approval but are later withdrawn from the market. Novartis h...